Literature DB >> 22139082

Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.

W Liu1, J Lindberg, G Sui, J Luo, L Egevad, T Li, C Xie, M Wan, S-T Kim, Z Wang, A R Turner, Z Zhang, J Feng, Y Yan, J Sun, G S Bova, C M Ewing, G Yan, M Gielzak, S D Cramer, R L Vessella, S L Zheng, H Grönberg, W B Isaacs, J Xu.   

Abstract

A clearer definition of the molecular determinants that drive the development and progression of prostate cancer (PCa) is urgently needed. Efforts to map recurrent somatic deletions in the tumor genome, especially homozygous deletions (HODs), have provided important positional information in the search for cancer-causing genes. Analyzing HODs in the tumors of 244 patients from two independent cohorts and 22 PCa xenografts using high-resolution single-nucleotide polymorphism arrays, herein we report the identification of CHD1, a chromatin remodeler, as one of the most frequently homozygously deleted genes in PCa, second only to PTEN in this regard. The HODs observed in CHD1, including deletions affecting only internal exons of CHD1, were found to completely extinguish the expression of mRNA of this gene in PCa xenografts. Loss of this chromatin remodeler in clinical specimens is significantly associated with an increased number of additional chromosomal deletions, both hemi- and homozygous, especially on 2q, 5q and 6q. Together with the deletions observed in HEK293 cells stably transfected with CHD1 small hairpin RNA, these data suggest a causal relationship. Downregulation of Chd1 in mouse prostate epithelial cells caused dramatic morphological changes indicative of increased invasiveness, but did not result in transformation. Indicating a new role of CHD1, these findings collectively suggest that distinct CHD1-associated alterations of genomic structure evolve during and are required for the development of PCa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139082      PMCID: PMC3667348          DOI: 10.1038/onc.2011.554

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.

Authors:  Guangchao Sui; Christina Soohoo; El Bachir Affar; Frédérique Gay; Yujiang Shi; William C Forrester; Yang Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  Gene silencing by a DNA vector-based RNAi technology.

Authors:  Guangchao Sui; Yang Shi
Journal:  Methods Mol Biol       Date:  2005

3.  Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing.

Authors:  Robert J Sims; Scott Millhouse; Chi-Fu Chen; Brian A Lewis; Hediye Erdjument-Bromage; Paul Tempst; James L Manley; Danny Reinberg
Journal:  Mol Cell       Date:  2007-11-30       Impact factor: 17.970

4.  Fine deletion mapping of chromosome 2q21-37 shows three preferentially deleted regions in oral cancer.

Authors:  Beyhan Cengiz; Mehmet Gunduz; Hitoshi Nagatsuka; Levent Beder; Esra Gunduz; Ryo Tamamura; Naila Mahmut; Kunihiro Fukushima; Mahmoud Al Sheikh Ali; Yoshio Naomoto; Kenji Shimizu; Noriyuki Nagai
Journal:  Oral Oncol       Date:  2006-07-20       Impact factor: 5.337

5.  Culture of mouse prostatic epithelial cells from genetically engineered mice.

Authors:  Wendy W Barclay; Scott D Cramer
Journal:  Prostate       Date:  2005-05-15       Impact factor: 4.104

6.  PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger.

Authors:  Zhiyong Deng; Meimei Wan; Guangchao Sui
Journal:  Mol Cell Biol       Date:  2007-03-12       Impact factor: 4.272

7.  Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.

Authors:  Rameen Beroukhim; Gad Getz; Leia Nghiemphu; Jordi Barretina; Teli Hsueh; David Linhart; Igor Vivanco; Jeffrey C Lee; Julie H Huang; Sethu Alexander; Jinyan Du; Tweeny Kau; Roman K Thomas; Kinjal Shah; Horacio Soto; Sven Perner; John Prensner; Ralph M Debiasi; Francesca Demichelis; Charlie Hatton; Mark A Rubin; Levi A Garraway; Stan F Nelson; Linda Liau; Paul S Mischel; Tim F Cloughesy; Matthew Meyerson; Todd A Golub; Eric S Lander; Ingo K Mellinghoff; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

8.  Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.

Authors:  Wennuan Liu; Bao-Li Chang; Scott Cramer; Patrick P Koty; Tao Li; Jishan Sun; Aubrey R Turner; Chris Von Kap-Herr; Peggy Bobby; Jianyu Rao; S Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

9.  Yin Yang 1 regulates the transcriptional activity of androgen receptor.

Authors:  Z Deng; M Wan; P Cao; A Rao; S D Cramer; G Sui
Journal:  Oncogene       Date:  2009-08-10       Impact factor: 9.867

10.  CHD1 motor protein is required for deposition of histone variant H3.3 into chromatin in vivo.

Authors:  Alexander Y Konev; Martin Tribus; Sung Yeon Park; Valerie Podhraski; Chin Yan Lim; Alexander V Emelyanov; Elena Vershilova; Vincenzo Pirrotta; James T Kadonaga; Alexandra Lusser; Dmitry V Fyodorov
Journal:  Science       Date:  2007-08-24       Impact factor: 47.728

View more
  47 in total

1.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Authors:  Michael A Augello; Deli Liu; Lesa D Deonarine; Brian D Robinson; Dennis Huang; Suzan Stelloo; Mirjam Blattner; Ashley S Doane; Elissa W P Wong; Yu Chen; Mark A Rubin; Himisha Beltran; Olivier Elemento; Andries M Bergman; Wilbert Zwart; Andrea Sboner; Noah Dephoure; Christopher E Barbieri
Journal:  Cancer Cell       Date:  2019-03-28       Impact factor: 31.743

Review 2.  The mutational landscape of prostate cancer.

Authors:  Christopher E Barbieri; Chris H Bangma; Anders Bjartell; James W F Catto; Zoran Culig; Henrik Grönberg; Jun Luo; Tapio Visakorpi; Mark A Rubin
Journal:  Eur Urol       Date:  2013-05-18       Impact factor: 20.096

Review 3.  Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes.

Authors:  Wangzhi Li; Alea A Mills
Journal:  Epigenomics       Date:  2014       Impact factor: 4.778

Review 4.  Chromodomain helicase DNA-binding proteins in stem cells and human developmental diseases.

Authors:  Joseph A Micucci; Ethan D Sperry; Donna M Martin
Journal:  Stem Cells Dev       Date:  2015-02-25       Impact factor: 3.272

5.  [Epigenetics in urothelial cancer: Pathogenesis, improving diagnostics and developing novel treatment options].

Authors:  G Niegisch; M J Hoffmann; E A Koutsogiannouli; W A Schulz
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

6.  A picture with more details is painted for prostate cancer.

Authors:  Wennuan Liu; Junjie Feng; Jianfeng Xu
Journal:  Asian J Androl       Date:  2012-07-30       Impact factor: 3.285

7.  Missense variants in the chromatin remodeler CHD1 are associated with neurodevelopmental disability.

Authors:  Genay O Pilarowski; Hilary J Vernon; Carolyn D Applegate; Leandros Boukas; Megan T Cho; Christina A Gurnett; Paul J Benke; Erin Beaver; Jennifer M Heeley; Livija Medne; Ian D Krantz; Meron Azage; Dmitriy Niyazov; Lindsay B Henderson; Ingrid M Wentzensen; Berivan Baskin; Maria J Guillen Sacoto; Gregory D Bowman; Hans T Bjornsson
Journal:  J Med Genet       Date:  2017-09-02       Impact factor: 6.318

Review 8.  Advancing precision medicine for prostate cancer through genomics.

Authors:  Sameek Roychowdhury; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

Review 9.  New strategies in prostate cancer: translating genomics into the clinic.

Authors:  Himisha Beltran; Mark A Rubin
Journal:  Clin Cancer Res       Date:  2012-12-17       Impact factor: 12.531

10.  Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma.

Authors:  Anna K Paulsson; Jordan A Holmes; Ann M Peiffer; Lance D Miller; Wennuan Liu; Jianfeng Xu; William H Hinson; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Waldemar Debinski; Michael D Chan
Journal:  J Neurooncol       Date:  2014-07-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.